Although UP II promoter has been used to specificallydrive TRAIL expression in bladder cancer cells, more novel strategies are needed toprevent the cytotoxicity of adenovirus-based gene therapy to normal cells [14-16]. Here, TNFSF10 is linked to urinary bladder cancer.